Skip to main navigation

Terms and Conditions

*

Client nav

About Arcturus

RNA Medicines

Technologies

Pipeline

Business Development

Publications

Investor Relations

Media Coverage

Categories

Year

Science “An mRNA vaccine with a twist—it copies itself—protects against COVID-19

April 21, 2022

Future of Personal Health “Rare Diseases”

March 29, 2022

TIME “2021 HEROES OF THE YEAR”

December 13, 2021

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, …

December 1, 2021

Mintz “Life Sciences CEO Interview: Joe Payne, President and CEO of Arcturus Th…

November 1, 2021

The Street “Two Stock Picks From the Woodstock of Micro-Caps”

October 18, 2021

Bio Integration “Voice Series COVID-19 Special Collection Part 2: Interview wit…

June 25, 2021

Nature Biopharma Dealmakers “Arcturus—a clinical-stage mRNA therapeutics and va…

June 1, 2021

Nature Biotechnology "A network analysis of COVID-19 mRNA vaccine patents"

May 12, 2021

BioCentury “Self-amplifying may be the next frontier in RNA therapies”

March 19, 2021

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 21 - 30 of 105

Arcturus-Covid19 Message.jpg

Nasdaq combined

Investor Home

Corporate Governance

Governance Highlights
Management Team
Board of Directors
Committee Composition

Financials & Filings

SEC Filings
Annual Reports
Quarterly Results

News & Events

Press Releases
Videos
Media Coverage
Presentations
Events

Stock Information

Stock Quote
Historical Price Lookup
Analyst Coverage

Investor Resources

Investor FAQ
Contact IR
Email Alerts

Home
Contact
Careers
Terms and Conditions
Privacy Policy

© 2024 Arcturus Therapeutics, Inc.

Search